1. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.J Clin Pharmacol2000;40:1419–27.
2. Schilsky RL. End points in cancer clinical trials and the drug approval process.Clin Cancer Res2002;8:935–8.
3. Tarantola G, Zito F, Gerundini P. PET instrumentation and reconstruction algorithms in whole-body applications.J Nucl Med2003;44:756–69.
4. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology.J Nucl Med2000;41:1369–79.
5. CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current